Durable clinical activity was observed with darlifarnib plus cabozantinib in advanced ccRCC, with response rates up to 50% and a median progression-free survival of 13 months. The combination was well tolerated, and a global Phase 1b study is ongoing to optimize dosing.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.